All In Biotech

Drug Trial Radar · NCT07802652

Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma

A Randomized Phase II Study of Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Feb 1, 2027

Primary completion

Nov 1, 2031

Study completion Nov 1, 2031

Sponsor

Lead sponsor
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AGENCE NATIONALE DE RECHERCHE
First posted
Sep 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this randomized phase II trial is to assess, independently in advanced/metastatic UPS and DDLPS, the antitumor activity of DT-7012 combined with doxorubicin as first-line systemic therapy.

Conditions

  • Undifferentiated Pleomorphic Sarcoma (UPS)
  • Dedifferentiated Liposarcoma (DDLPS)

Interventions

  • DT-7012Drug

    DT-7012 administered IV at 10 mg/kg on Day 1 of each 21-day cycle for a total maximum of 24 months

  • DoxorubicinDrug

    Doxorubicin administered IV at 75 mg/m2 on Day 1 of each 21-day cycle, up to 6 cycles or according to cumulative dose limits and local standards

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 6-month progression-free rate (PFR6)Time frame: from the enrollment to 24 weeks after treatment onset

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gustave Roussy

    Villejuif, Val de Marne, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.